Aura Biosciences (NASDAQ:AURA) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Aura Biosciences (NASDAQ:AURA) posted its quarterly earnings data on Tuesday. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Stock Down 1.1 %

Shares of NASDAQ:AURA traded down $0.12 during midday trading on Wednesday, hitting $10.53. The stock had a trading volume of 36,363 shares, compared to its average volume of 175,139. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The stock has a 50 day moving average price of $9.69 and a two-hundred day moving average price of $8.49.

Wall Street Analyst Weigh In

Several analysts recently commented on AURA shares. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. BTIG Research upped their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Scotiabank increased their price target on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Aura Biosciences presently has an average rating of “Buy” and an average target price of $23.00.

Insider Buying and Selling at Aura Biosciences

In other news, CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at approximately $1,615,340.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Aura Biosciences news, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at $1,615,340.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Los Pinos Elisabet De sold 24,992 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the transaction, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,259 shares of company stock valued at $780,699 over the last quarter. Corporate insiders own 5.40% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.